CY2013029PI2 - NEW INSULIN DERIVATIVES - Google Patents

NEW INSULIN DERIVATIVES

Info

Publication number: CY2013029PI2
Authority: CY; Cyprus
Prior art keywords: insulin derivatives; new insulin; new; derivatives; insulin
Prior art date: 2003-08-05

Application number

CY2013029C

Other languages

Greek (el)

Original Assignee

Novo Nordisk A/S

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-08-05

Filing date

2013-07-08

Publication date

2015-11-04

2013-07-08 Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S

2015-11-04 Publication of CY2013029PI2 publication Critical patent/CY2013029PI2/en

2015-11-04 Publication of CY2013029PI1 publication Critical patent/CY2013029PI1/en

Links

NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Diabetes (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Endocrinology (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Toxicology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Emergency Medicine (AREA)
Hematology (AREA)
Obesity (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

CY2013029C 2003-08-05 2013-07-08 NEW INSULIN DERIVATIVES CY2013029PI1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DKPA200301129		2003-08-05
US49545103P	2003-08-14	2003-08-14
EP04739008A EP1660531A2 (en)	2003-08-05	2004-07-22	Novel insulin derivatives

Publications (2)

Publication Number	Publication Date
CY2013029PI2 true CY2013029PI2 (en)	2015-11-04
CY2013029PI1 CY2013029PI1 (en)	2015-11-04

Family

ID=34117520

Family Applications (5)

Application Number	Title	Priority Date	Filing Date
CY20131100259T CY1113850T1 (en)	2003-08-05	2013-03-28	NEW INSULIN PRODUCERS
CY2013027C CY2013027PI1 (en)	2003-08-05	2013-07-04	NEW INSULIN DERIVATIVES
CY2013029C CY2013029PI1 (en)	2003-08-05	2013-07-08	NEW INSULIN DERIVATIVES
CY2013029C CY2013029I2 (en)	2003-08-05	2023-12-28	NEW INSULIN DERIVATIVES
CY2013027C CY2013027I2 (en)	2003-08-05	2024-01-31	NEW INSULIN DERIVATIVES

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
CY20131100259T CY1113850T1 (en)	2003-08-05	2013-03-28	NEW INSULIN PRODUCERS
CY2013027C CY2013027PI1 (en)	2003-08-05	2013-07-04	NEW INSULIN DERIVATIVES

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
CY2013029C CY2013029I2 (en)	2003-08-05	2023-12-28	NEW INSULIN DERIVATIVES
CY2013027C CY2013027I2 (en)	2003-08-05	2024-01-31	NEW INSULIN DERIVATIVES

Country Status (18)

Country	Link
US (3)	US7615532B2 (en)
EP (3)	EP1660531A2 (en)
JP (1)	JP4463814B2 (en)
KR (1)	KR101159559B1 (en)
AU (2)	AU2004261353B2 (en)
BE (2)	BE2013C035I2 (en)
BR (1)	BRPI0413276B8 (en)
CA (1)	CA2531988C (en)
CY (5)	CY1113850T1 (en)
FR (2)	FR13C0035I2 (en)
HU (1)	HUS1300033I1 (en)
IL (1)	IL172980A (en)
LU (2)	LU92213I2 (en)
MX (1)	MXPA06001283A (en)
NO (5)	NO340925B1 (en)
PL (1)	PL2107069T3 (en)
RU (1)	RU2518460C2 (en)
WO (1)	WO2005012347A2 (en)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK1648933T3 (en) *	2003-07-25	2009-09-07	Conjuchem Biotechnologies Inc	Prolonged insulin derivatives and methods
CA2531988C (en) *	2003-08-05	2016-06-28	Novo Nordisk A/S	Novel insulin derivatives
EP2256130B1 (en) *	2005-02-02	2013-09-25	Novo Nordisk A/S	Novel insulin derivatives
US20080171695A1 (en) *	2005-02-02	2008-07-17	Novo Nordisk A/S	Insulin Derivatives
ES2371361T3 (en)	2005-12-28	2011-12-30	Novo Nordisk A/S	COMPOSITIONS THAT INCLUDE AN INSULIN ACILADA AND ZINC AND METHOD OF PRODUCTION OF SUCH COMPOSITIONS.
DE602007009496D1 (en)	2006-02-27	2010-11-11	Novo Nordisk As	INSULIN DERIVATIVES
WO2007104736A2 (en) *	2006-03-13	2007-09-20	Novo Nordisk A/S	Acylated single chain insulin
US8293965B2 (en)	2006-04-28	2012-10-23	Kimberly-Clark Worldwide, Inc.	Antimicrobial site dressings
EP2015770B1 (en) *	2006-05-09	2012-09-26	Novo Nordisk A/S	Insulin derivative
WO2007128815A1 (en)	2006-05-09	2007-11-15	Novo Nordisk A/S	Insulin derivative
CN101437849B (en) *	2006-05-09	2015-09-30	诺沃-诺迪斯克有限公司	Insulin derivatives
JP5097900B2 (en) *	2006-06-27	2012-12-12	独立行政法人物質・材料研究機構	Method for producing active ester of organic acid or derivative thereof
CN101573133B (en) *	2006-07-31	2014-08-27	诺沃-诺迪斯克有限公司	PEGylated, extended insulins
RU2524150C2 (en)	2006-09-22	2014-07-27	Ново Нордиск А/С	Protease-resistant insulin analogues
JP5496082B2 (en)	2007-04-30	2014-05-21	ノボ・ノルデイスク・エー／エス	Method for drying protein composition, dry protein composition, and pharmaceutical composition containing dry protein
CN101677944A (en) *	2007-06-01	2010-03-24	诺沃-诺迪斯克有限公司	stable non-aqueous pharmaceutical composition
US20110144010A1 (en)	2007-06-01	2011-06-16	Novo Nordisk A/S	Spontaneously Dispersible Preconcentrates Including a Peptide Drug in a Solid or Semisolid Carrier
JP5552046B2 (en) *	2007-06-13	2014-07-16	ノボ・ノルデイスク・エー／エス	Pharmaceutical preparation containing an insulin derivative
JP5721432B2 (en) *	2007-08-15	2015-05-20	ノボ・ノルデイスク・エー／エス	Insulin having an acyl moiety containing an amino acid-containing alkylene glycol repeating unit
US9150633B2 (en)	2007-08-15	2015-10-06	Novo Nordisk A/S	Insulin analogues with an acyl and alkylene glycol moiety
CN101157725B (en) *	2007-10-24	2012-07-25	中国药科大学	Preparation method of human insulin analogue and usage thereof
EP2217621B1 (en)	2007-11-08	2015-04-22	Novo Nordisk A/S	Insulin derivative
BRPI0820535B8 (en)	2007-11-16	2021-05-25	Novo Nordisk As	pharmaceutical compositions containing insulin and an insulinotropic peptide
WO2009112583A2 (en)	2008-03-14	2009-09-17	Novo Nordisk A/S	Protease-stabilized insulin analogues
HUE032284T2 (en)	2008-03-18	2017-09-28	Novo Nordisk As	Protease stabilized, acylated insulin analogues
ES2561208T3 (en)	2008-09-12	2016-02-25	Novo Nordisk A/S	Acylation method of a peptide or protein
JP4959005B2 (en)	2008-10-30	2012-06-20	ノボ・ノルデイスク・エー／エス	Treatment of diabetes mellitus with insulin injections less than daily injection frequency
CN102361647B (en)	2009-01-23	2018-02-16	诺沃-诺迪斯克有限公司	FGF21 derivatives and its application with albumin combination agent A B C D E
EP2493919A1 (en)	2009-10-30	2012-09-05	Novo Nordisk A/S	Derivatives of cgrp
CA2786953A1 (en) *	2010-01-12	2011-07-21	Florian Anders Foeger	Pharmaceutical compositions for oral administration of insulin peptides
CN102812039B (en)	2010-02-16	2016-01-20	诺沃—诺迪斯克有限公司	Conjugated protein
ES2582590T3 (en)	2010-02-16	2016-09-13	Novo Nordisk A/S	Purification method
MX2012012943A (en)	2010-05-10	2012-11-29	Novo Nordisk As	Process for the preparation of insulin-zinc complexes.
US20130345397A1 (en)	2010-05-25	2013-12-26	Andrea Robinson	Methods for the synthesis of dicarba bridges in peptides
WO2011161083A1 (en)	2010-06-23	2011-12-29	Novo Nordisk A/S	Human insulin containing additional disulfide bonds
JP5973427B2 (en)	2010-06-23	2016-08-23	ノヴォノルディスクアー／エス	Insulin analogues containing additional disulfide bonds
KR20130036290A (en) *	2010-06-23	2013-04-11	노보 노르디스크 에이/에스	Insulin derivatives containing additional disulfide bonds
WO2012049307A2 (en)	2010-10-15	2012-04-19	Novo Nordisk A/S	Novel n-terminally modified insulin derivatives
PL2632478T3 (en)	2010-10-27	2020-03-31	Novo Nordisk A/S	Treating diabetes melitus using insulin injections administered with varying injection intervals
DK2632478T3 (en) *	2010-10-27	2019-10-07	Novo Nordisk As	TREATMENT OF DIABETES MELITUS USING INSULIN INJECTIONS SUBMITTED AT VARIOUS INJECTION INTERVALS
WO2012080320A1 (en)	2010-12-14	2012-06-21	Novo Nordisk A/S	Fast-acting insulin in combination with long-acting insulin
JP2014510516A (en)	2011-02-15	2014-05-01	ノヴォノルディスクアー／エス	Long acting IL-1 receptor antagonist
RU2013145013A (en) *	2011-03-28	2015-05-10	Ново Нордиск А/С	NEW GLUCAGON ANALOGUES
EP2696847A1 (en)	2011-04-14	2014-02-19	Novo Nordisk A/S	Fatty acid acylated amino acids for oral peptide delivery
CN103596584B (en)	2011-06-15	2016-12-14	诺沃—诺迪斯克有限公司	Polysubstituted insulin
AU2012311484B2 (en) *	2011-09-23	2017-04-13	Novo Nordisk A/S	Novel glucagon analogues
KR20140104994A (en) *	2011-12-15	2014-08-29	샹하이 헨그루이 파마수티컬 컴퍼니 리미티드	Human Insulin Analogue and Acylated Derivative thereof
US20140357838A1 (en)	2011-12-21	2014-12-04	Novo Nordisk A/S	N-Terminally Modified Insulin Derivatives
CN104364260B (en)	2012-04-11	2017-02-22	诺和诺德股份有限公司	insulin formulations
US20160031962A1 (en) *	2012-04-20	2016-02-04	Kleomenis K. Barlos	Solid phase peptide synthesis of insulin using side chain achored lysine
EP2844274B1 (en)	2012-05-01	2019-03-20	Novo Nordisk A/S	Pharmaceutical composition
US20150111820A1 (en)	2012-07-09	2015-04-23	Novo Nordisk A/S	Novel use of insulin derivatives
UA116217C2 (en)	2012-10-09	2018-02-26	Санофі	Exendin-4 derivatives as dual glp1/glucagon agonists
JP6285447B2 (en)	2012-10-17	2018-02-28	ノヴォノルディスクアー／エス	Fatty acylated D-amino acids for oral peptide delivery
AU2013366692B2 (en)	2012-12-21	2017-11-23	Sanofi	Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists
CN105188736A (en) *	2013-03-20	2015-12-23	诺和诺德股份有限公司	Insulin dosing regimen
EP2986313B1 (en)	2013-04-18	2019-06-12	Novo Nordisk A/S	Stable, protracted glp-1/glucagon receptor co-agonists for medical use
EP2991672A1 (en)	2013-04-30	2016-03-09	Novo Nordisk A/S	Novel administration regime
GB201315335D0 (en)	2013-08-29	2013-10-09	Of Singapore	Amino diacids containing peptide modifiers
JP6499184B2 (en)	2013-10-07	2019-04-10	ノヴォノルディスクアー／エス	Novel derivatives of insulin analogues
FR3013049B1 (en)	2013-11-14	2015-11-13	You-Ping Chan	ANALOGUE OF INSULIN GLARGINE
EP3080154B1 (en)	2013-12-13	2018-02-07	Sanofi	Dual glp-1/gip receptor agonists
WO2015086733A1 (en)	2013-12-13	2015-06-18	Sanofi	Dual glp-1/glucagon receptor agonists
WO2015086728A1 (en)	2013-12-13	2015-06-18	Sanofi	Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
EP3080152A1 (en)	2013-12-13	2016-10-19	Sanofi	Non-acylated exendin-4 peptide analogues
MX2016010599A (en)	2014-02-18	2016-11-18	Novo Nordisk As	Stable glucagon analogues and use for treatment of hypoglycaemia.
AR099569A1 (en)	2014-02-28	2016-08-03	Novo Nordisk As	INSULIN DERIVATIVES AND THE MEDICAL USES OF THESE
TW201625670A (en)	2014-04-07	2016-07-16	賽諾菲公司	Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4
TW201625668A (en)	2014-04-07	2016-07-16	賽諾菲公司	Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists
TW201625669A (en)	2014-04-07	2016-07-16	賽諾菲公司	Peptidic dual GLP-1/glucagon receptor agonists derived from Exendin-4
US10570184B2 (en)	2014-06-04	2020-02-25	Novo Nordisk A/S	GLP-1/glucagon receptor co-agonists for medical use
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
AR105319A1 (en)	2015-06-05	2017-09-27	Sanofi Sa	PROPHARMS THAT INCLUDE A DUAL AGONIST GLU-1 / GLUCAGON CONJUGATE HIALURONIC ACID CONNECTOR
TW201706291A (en)	2015-07-10	2017-02-16	賽諾菲公司	New EXENDIN-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists
CN108368163A (en)	2015-08-25	2018-08-03	诺和诺德股份有限公司	Novel insulin derivates and its medical usage
US20190010206A1 (en)	2015-08-25	2019-01-10	Novo Nordisk A/S	Novel Insulin Derivatives and the Medical Uses Hereof
WO2018024186A1 (en)	2016-08-02	2018-02-08	江苏恒瑞医药股份有限公司	Acylated derivative of human insulin or analogue thereof
WO2018096164A1 (en)	2016-11-28	2018-05-31	Novo Nordisk A/S	Insulin degludec for treating diabetes
US11278596B2 (en)	2016-11-28	2022-03-22	Novo Nordisk A/S	Insulin degludec in cardiovascular conditions
JP2019535791A (en)	2016-11-28	2019-12-12	ノヴォノルディスクアー／エス	Insulin degludec for improved glycemic control and reduction of acute and long-term diabetic complications
PE20210857A1 (en)	2016-12-16	2021-05-18	Novo Nordisk As	PHARMACEUTICAL COMPOSITIONS CONTAINING INSULIN
JOP20190273A1 (en) *	2017-05-26	2019-11-24	Lilly Co Eli	Insulin treated with basil complex
CN111094572B (en)	2018-02-09	2023-04-04	江苏恒瑞医药股份有限公司	Codon-optimized human insulin analogue precursor gene and signal peptide gene
EP3805257A4 (en)	2018-05-24	2022-03-16	Jiangsu Hengrui Medicine Co., Ltd.	Method for preparing precursor of recombinant human insulin or analogue thereof
WO2020002428A1 (en)	2018-06-26	2020-01-02	Novo Nordisk A/S	System providing dose recommendations for basal insulin titration
US10335464B1 (en)	2018-06-26	2019-07-02	Novo Nordisk A/S	Device for titrating basal insulin
KR102666154B1 (en)	2018-08-08	2024-05-20	주식회사 대웅제약	Long-acting Insulin Analog and Derivatives Thereof
KR20200080747A (en)	2018-12-27	2020-07-07	주식회사 폴루스	An Enzymatic Conversion Composition for Producing Insulin from Proinsulin and a Method for Producing Insulin from Proinsulin Using the Same
KR20200080748A (en)	2018-12-27	2020-07-07	주식회사 폴루스	A Method for Purifying Proinsulin Using Anion Exchange Chromatography
US12343383B2 (en)	2019-07-12	2025-07-01	Novo Nordisk A/S	High concentration insulin formulation
TWI844709B (en)	2019-07-31	2024-06-11	美商美國禮來大藥廠	Relaxin analogs and methods of using the same
CN118754967A (en)	2019-12-30	2024-10-11	甘李药业股份有限公司	Insulin derivatives
EP4149516A4 (en)	2020-05-15	2024-11-13	Eli Lilly and Company	ACYLATED INSULIN COMPOUNDS WITH EXTENDED ACTION
CN113773398B (en) *	2020-06-10	2023-05-23	宁波鲲鹏生物科技有限公司	De-glu insulin derivative and application thereof
EP4180060A1 (en)	2021-11-15	2023-05-17	Adocia	Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4299057A1 (en)	2022-06-30	2024-01-03	Adocia	Solid compositions comprising a peptide or a protein and an acylated amino acid
WO2023084118A1 (en)	2021-11-15	2023-05-19	Adocia	Solid compositions comprising a peptide or a protein and an acylated amino acid
US20250340610A1 (en)	2022-01-28	2025-11-06	Gan & Lee Pharmaceuticals Co., Ltd.	Acylated insulin
EP4299071A1 (en)	2022-07-01	2024-01-03	Adocia	Compositions comprising a peptide or a protein and an acylated amino acid
WO2025104600A1 (en) *	2023-11-15	2025-05-22	Ambio, Inc.	Insulin analogs for the treatment of human metabolic disorder and disease

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1212679B (en)	1957-08-03	1966-03-17	Novo Terapeutisk Labor As	Process for the preparation of insulin solutions
GB1042194A (en)	1962-04-30	1966-09-14	Olin Mathieson	Insulin preparations
US3528960A (en)	1968-10-07	1970-09-15	Lilly Co Eli	N-carboxyaroyl insulins
US3868358A (en)	1971-04-30	1975-02-25	Lilly Co Eli	Protamine-insulin product
GB1492997A (en)	1976-07-21	1977-11-23	Nat Res Dev	Insulin derivatives
JPS5767548A (en)	1980-10-14	1982-04-24	Shionogi & Co Ltd	Insulin analog and its preparation
FI78616C (en)	1982-02-05	1989-09-11	Novo Industri As	Process for preparing an infused stabilized insulin solution having an elevated zinc content
PH25772A (en)	1985-08-30	1991-10-18	Novo Industri As	Insulin analogues, process for their preparation
NZ222907A (en)	1986-12-16	1990-08-28	Novo Industri As	Preparation for intranasal administration containing a phospholipid absorption enhancing system
US5605884A (en)	1987-10-29	1997-02-25	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Factor VIII formulations in high ionic strength media
US4877608A (en)	1987-11-09	1989-10-31	Rorer Pharmaceutical Corporation	Pharmaceutical plasma protein formulations in low ionic strength media
JPH01254699A (en)	1988-04-05	1989-10-11	Kodama Kk	Insulin derivative and use thereof
DE3827533A1 (en)	1988-08-13	1990-02-15	Hoechst Ag	PHARMACEUTICAL PREPARATION FOR TREATING THE DIABETES MELLITUS
HUT56857A (en)	1988-12-23	1991-10-28	Novo Nordisk As	Human insulin analogues
IL93282A (en)	1989-02-09	1995-08-31	Lilly Co Eli	Insulin analogs
IT1240314B (en)	1989-09-28	1993-12-07	Immunobiology Research Institutes, Inc.	STABILIZED AQUEOUS FORMULATIONS OF SMALL PEPTIDES.
JP3122128B2 (en)	1989-12-21	2001-01-09	ノボノルディスクアクティーゼルスカブ	Peptide preparation
DK45590D0 (en)	1990-02-21	1990-02-21	Novo Nordisk As
JP3193398B2 (en)	1991-07-23	2001-07-30	サンデン株式会社	Showcase
DE69232847T2 (en)	1991-12-20	2003-09-11	Novo Nordisk A/S, Bagsvaerd	STABILIZED PHARMACEUTICAL FORMULATION CONTAINING GROWTH HORMONE AND HISTIDINE
US6869930B1 (en)	1993-09-17	2005-03-22	Novo Nordisk A/S	Acylated insulin
US6011007A (en)	1993-09-17	2000-01-04	Novo Nordisk A/S	Acylated insulin
EP1132404A3 (en)	1993-09-17	2002-03-27	Novo Nordisk A/S	Acylated insulin
US5652216A (en)	1994-05-26	1997-07-29	Novo Nordisk A/S	Pharmaceutical preparation
AU3562195A (en)	1994-10-04	1996-04-26	Novo Nordisk A/S	Preparations containing aspb28 human insulin and nicotinamide
US5646242A (en)	1994-11-17	1997-07-08	Eli Lilly And Company	Selective acylation of epsilon-amino groups
US5830999A (en)	1995-01-26	1998-11-03	Regents Of The University Of California	Stabilization of insulin through ligand binding interations
US6251856B1 (en) *	1995-03-17	2001-06-26	Novo Nordisk A/S	Insulin derivatives
CZ289343B6 (en)	1995-03-17	2002-01-16	Novo Nordisk A/S	Insulin derivative and pharmaceutical preparations for treating diabetes mellitus
ES2434840T3 (en)	1995-07-27	2013-12-17	Genentech, Inc.	Formulation of stable isotonic lyophilized protein
US6451970B1 (en)	1996-02-21	2002-09-17	Novo Nordisk A/S	Peptide derivatives
US5898267A (en) *	1996-04-10	1999-04-27	Mcdermott; Kevin	Parabolic axial lighting device
US5866538A (en)	1996-06-20	1999-02-02	Novo Nordisk A/S	Insulin preparations containing NaCl
US5905140A (en)	1996-07-11	1999-05-18	Novo Nordisk A/S, Novo Alle	Selective acylation method
ATE278711T1 (en)	1996-07-11	2004-10-15	Novo Nordisk As	METHOD FOR SELECTIVE ACETYLATION
US5763401A (en)	1996-07-12	1998-06-09	Bayer Corporation	Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
PT821006E (en)	1996-07-26	2004-09-30	Aventis Pharma Gmbh	INSULIN DERIVATIVES WITH ENHANCED ZINC LINK
IL119029A0 (en)	1996-08-07	1996-11-14	Yeda Res & Dev	Long-acting drugs and pharamaceutical compositions comprising them
US5898067A (en) *	1997-02-07	1999-04-27	Novo Nordisk A/S	Crystallization of proteins
EP1005490B1 (en) *	1997-03-20	2006-03-29	Novo Nordisk A/S	Zinc free insulin crystals for use in pulmonary compositions
JP2001518915A (en)	1997-03-20	2001-10-16	ノボノルディスクアクティーゼルスカブ	Preparation of therapeutic powder by co-precipitation of insulin and absorption enhancer
JP2001518916A (en)	1997-03-20	2001-10-16	ノボノルディスクアクティーゼルスカブ	Therapeutic powder formulation for pulmonary administration containing crystalline insulin
US7097845B2 (en)	1997-04-23	2006-08-29	Jacob Sten Petersen	Combinations of antigen and mucosal binding component for inducing specific immunological tolerance
DK1283051T3 (en)	1997-06-13	2006-10-16	Lilly Co Eli	Stable insulin formulations
RU2218349C2 (en) *	1997-10-24	2003-12-10	Ново Нордиск А/С	Aggregates of derivatives of human insulin
JP2001521006A (en)	1997-10-24	2001-11-06	イーライ・リリー・アンド・カンパニー	Insoluble insulin composition
US20020155994A1 (en)	1997-10-24	2002-10-24	Svend Havelund	Aggregates of human insulin derivatives
US6451762B1 (en)	1997-10-24	2002-09-17	Novo Nordisk A/S	Aggregates of human insulin derivatives
ZA989744B (en)	1997-10-31	2000-04-26	Lilly Co Eli	Method for administering acylated insulin.
US6531448B1 (en)	1997-12-23	2003-03-11	Eli Lilly And Company	Insoluble compositions for controlling blood glucose
WO1999034821A1 (en)	1998-01-09	1999-07-15	Novo Nordisk A/S	Stabilised insulin compositions
US6211144B1 (en)	1998-10-16	2001-04-03	Novo Nordisk A/S	Stable concentrated insulin preparations for pulmonary delivery
UA65636C2 (en)	1998-10-16	2004-04-15	Ново Нордіск А/С	Concentrated aqueous insulin formulations of high stability suitable for pulmonary delivery
DK1820516T3 (en)	1999-02-22	2013-10-28	Univ Connecticut	New albumin-free factor VIII preparations
JP2002543092A (en)	1999-04-27	2002-12-17	イーライ・リリー・アンド・カンパニー	Insulin crystals for pulmonary administration
GB9930882D0 (en)	1999-12-30	2000-02-23	Nps Allelix Corp	GLP-2 formulations
DE10022092A1 (en)	2000-05-08	2001-11-15	Aventis Behring Gmbh	Stabilized protein preparation and process for its preparation
US6652886B2 (en)	2001-02-16	2003-11-25	Expression Genetics	Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
DE10114178A1 (en)	2001-03-23	2002-10-10	Aventis Pharma Gmbh	Zinc-free and low-zinc insulin preparations with improved stability
WO2003002136A2 (en)	2001-06-28	2003-01-09	Novo Nordisk A/S	Stable formulation of modified glp-1
CZ2004710A3 (en)	2001-12-20	2005-02-16	Eli Lilly And Company	Insulin compound exhibiting protracted activity
AU2003208316A1 (en)	2002-03-13	2003-09-22	Novo Nordisk A/S	Minimising body weight gain in insulin treatment
JP5599543B2 (en)	2002-05-07	2014-10-01	ノヴォノルディスクアー／エス	Soluble formulation containing monomeric insulin and acylated insulin
US20050232899A1 (en)	2002-05-31	2005-10-20	Aradigm Corporation	Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b
US20040002451A1 (en)	2002-06-20	2004-01-01	Bruce Kerwin	Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
KR100615389B1 (en)	2002-08-23	2006-08-25	(주)헬릭서	Health food comprising the extract of Actinidia arguta and related species for the prevention and improvement of allergic disease and non-allergic inflammatory disease
RU2329823C2 (en)	2002-10-29	2008-07-27	Алза Корпорейшн	Stabilising of solid polypeptide particles
US20040138099A1 (en)	2002-11-29	2004-07-15	Draeger Eberhard Kurt	Insulin administration regimens for the treatment of subjects with diabetes
CN1771040B (en)	2003-02-07	2010-06-16	味之素株式会社	Therapeutic agent for diabetes
CN100422328C (en)	2003-02-19	2008-10-01	诺瓦提斯公司	Glycoprotein antigen SIMA135 expressed in human metastatic tumor cells
BRPI0408105A (en)	2003-03-04	2006-03-01	Thetechnology Dev Company Ltd	drug and cell therapy delivery system
EP1641487B1 (en)	2003-06-25	2012-02-29	Novo Nordisk Health Care AG	Liquid composition of factor vii polypeptides
US20050054818A1 (en)	2003-07-02	2005-03-10	Brader Mark Laurence	Crystalline compositions for controlling blood glucose
CA2531988C (en)	2003-08-05	2016-06-28	Novo Nordisk A/S	Novel insulin derivatives
DK2275439T3 (en)	2003-08-05	2014-05-12	Novo Nordisk As	Hitherto unknown insulin derivatives
JP5653572B2 (en)	2003-08-14	2015-01-14	ノボノルディスクヘルスケアアクチェンゲゼルシャフト	Liquid aqueous pharmaceutical composition of factor VII polypeptide
WO2005021022A2 (en)	2003-09-01	2005-03-10	Novo Nordisk A/S	Stable formulations of peptides
ES2229931B1 (en)	2003-10-03	2006-01-16	Grifols, S.A.	BILOGICALLY STABLE LIQUID COMPOSITION OF FVIII, FVW OR HUMAN FVIII / FVW COMPLEX.
EP1687428A1 (en)	2003-11-14	2006-08-09	Novo Nordisk A/S	Processes for making acylated insulin
WO2005063298A1 (en)	2003-12-23	2005-07-14	Pharmacia Corporation	Stable growth hormone liquid formulation
US7279457B2 (en)	2004-03-12	2007-10-09	Biodel, Inc.	Rapid acting drug delivery compositions
CA2567309A1 (en)	2004-06-01	2005-12-15	Ares Trading S.A.	Method of stabilizing proteins
CA2576549C (en)	2004-08-12	2011-01-18	Schering Corporation	Stable pegylated interferon formulation
CA2576519C (en)	2004-08-17	2013-05-21	Regeneron Pharmaceuticals, Inc.	Il-1 antagonist formulations
WO2006051103A2 (en)	2004-11-12	2006-05-18	Novo Nordisk A/S	Stable formulations of peptides
US8263551B2 (en)	2004-11-22	2012-09-11	Novo Nordisk A/S	Soluble, stable insulin-containing formulations with a protamine salt
CA2593112A1 (en)	2005-01-21	2006-07-27	Alza Corporation	Therapeutic peptide formulations for coating microneedles with improved stability containing at least one counterion
EP2256130B1 (en) *	2005-02-02	2013-09-25	Novo Nordisk A/S	Novel insulin derivatives
ES2371361T3 (en)	2005-12-28	2011-12-30	Novo Nordisk A/S	COMPOSITIONS THAT INCLUDE AN INSULIN ACILADA AND ZINC AND METHOD OF PRODUCTION OF SUCH COMPOSITIONS.
DE602007009496D1 (en)	2006-02-27	2010-11-11	Novo Nordisk As	INSULIN DERIVATIVES
EP2012817A2 (en)	2006-04-12	2009-01-14	Biodel, Inc.	Rapid acting and long acting insulin combination formulations
EP2015770B1 (en)	2006-05-09	2012-09-26	Novo Nordisk A/S	Insulin derivative
JP5552046B2 (en)	2007-06-13	2014-07-16	ノボ・ノルデイスク・エー／エス	Pharmaceutical preparation containing an insulin derivative
BRPI0820535B8 (en)	2007-11-16	2021-05-25	Novo Nordisk As	pharmaceutical compositions containing insulin and an insulinotropic peptide
TWI451876B (en)	2008-06-13	2014-09-11	Lilly Co Eli	Pegylated insulin lispro compounds

2004
- 2004-07-22 CA CA2531988A patent/CA2531988C/en not_active Expired - Fee Related
- 2004-07-22 KR KR1020067002551A patent/KR101159559B1/en not_active Expired - Lifetime
- 2004-07-22 BR BRPI0413276A patent/BRPI0413276B8/en active IP Right Grant
- 2004-07-22 MX MXPA06001283A patent/MXPA06001283A/en active IP Right Grant
- 2004-07-22 PL PL09165072T patent/PL2107069T3/en unknown
- 2004-07-22 EP EP04739008A patent/EP1660531A2/en not_active Withdrawn
- 2004-07-22 EP EP10174490.2A patent/EP2264065B1/en not_active Expired - Lifetime
- 2004-07-22 WO PCT/DK2004/000511 patent/WO2005012347A2/en not_active Ceased
- 2004-07-22 JP JP2006522233A patent/JP4463814B2/en not_active Expired - Lifetime
- 2004-07-22 EP EP09165072A patent/EP2107069B1/en not_active Expired - Lifetime
- 2004-07-22 AU AU2004261353A patent/AU2004261353B2/en active Active
2006
- 2006-01-05 IL IL172980A patent/IL172980A/en active Protection Beyond IP Right Term
- 2006-01-30 US US11/343,005 patent/US7615532B2/en active Active
- 2006-03-02 NO NO20061026A patent/NO340925B1/en active Protection Beyond IP Right Term
2008
- 2008-12-29 RU RU2008152033/04A patent/RU2518460C2/en active
2009
- 2009-09-16 US US12/560,833 patent/US8828923B2/en not_active Expired - Lifetime
2010
- 2010-02-10 AU AU2010200497A patent/AU2010200497B2/en active Active
2013
- 2013-03-28 CY CY20131100259T patent/CY1113850T1/en unknown
- 2013-06-10 LU LU92213C patent/LU92213I2/en unknown
- 2013-06-11 BE BE2013C035C patent/BE2013C035I2/fr unknown
- 2013-06-19 LU LU92226C patent/LU92226I2/en unknown
- 2013-06-19 BE BE2013C038C patent/BE2013C038I2/fr unknown
- 2013-07-04 CY CY2013027C patent/CY2013027PI1/en unknown
- 2013-07-04 FR FR13C0035C patent/FR13C0035I2/en active Active
- 2013-07-05 FR FR13C0038C patent/FR13C0038I1/en active Active
- 2013-07-08 CY CY2013029C patent/CY2013029PI1/en unknown
- 2013-07-18 HU HUS1300033C patent/HUS1300033I1/en unknown
2014
- 2014-08-06 US US14/453,276 patent/US20140349925A1/en not_active Abandoned
2018
- 2018-01-11 NO NO2018002C patent/NO2018002I2/en unknown
- 2018-01-11 NO NO2018003C patent/NO2018003I1/en unknown
2023
- 2023-12-28 CY CY2013029C patent/CY2013029I2/en unknown
2024
- 2024-01-16 NO NO2024004C patent/NO2024004I1/en unknown
- 2024-01-16 NO NO2024003C patent/NO2024003I1/en unknown
- 2024-01-31 CY CY2013027C patent/CY2013027I2/en unknown

Also Published As

Publication number	Publication date
CY2013027I1 (en)	2024-09-20
BE2013C038I2 (en)	2023-12-14
US20100009899A1 (en)	2010-01-14
HUS1300033I1 (en)	2016-08-29
IL172980A (en)	2013-10-31
BRPI0413276B1 (en)	2020-03-03
NO340925B1 (en)	2017-07-17
EP2264065A2 (en)	2010-12-22
FR13C0035I1 (en)	2013-08-09
CY2013027PI2 (en)	2015-11-04
EP2107069A3 (en)	2009-11-25
BRPI0413276A (en)	2006-10-10
US20140349925A1 (en)	2014-11-27
EP2107069A2 (en)	2009-10-07
CA2531988C (en)	2016-06-28
EP1660531A2 (en)	2006-05-31
LU92213I2 (en)	2013-08-23
IL172980A0 (en)	2006-06-11
NO2024004I1 (en)	2024-01-16
NO2018002I2 (en)	2018-08-20
WO2005012347A2 (en)	2005-02-10
CY2013027I2 (en)	2024-09-20
AU2004261353B2 (en)	2009-12-10
AU2010200497A1 (en)	2010-03-04
NO2018003I1 (en)	2018-01-11
EP2107069B1 (en)	2013-01-16
CY2013029I2 (en)	2024-09-20
CA2531988A1 (en)	2005-02-10
MXPA06001283A (en)	2006-04-11
CY2013029I1 (en)	2024-09-20
EP2264065A3 (en)	2011-07-27
LU92226I9 (en)	2018-11-19
CY2013029PI1 (en)	2015-11-04
CY2013027PI1 (en)	2015-11-04
US7615532B2 (en)	2009-11-10
US20060183668A1 (en)	2006-08-17
US8828923B2 (en)	2014-09-09
JP4463814B2 (en)	2010-05-19
FR13C0038I1 (en)	2013-08-09
NO2018002I1 (en)	2018-01-11
JP2007523881A (en)	2007-08-23
AU2010200497B2 (en)	2014-10-23
CY1113850T1 (en)	2015-11-04
KR20060132543A (en)	2006-12-21
WO2005012347A3 (en)	2005-04-14
AU2004261353A1 (en)	2005-02-10
LU92226I2 (en)	2015-04-29
FR13C0035I2 (en)	2014-03-07
NO20061026L (en)	2006-03-02
PL2107069T3 (en)	2013-06-28
RU2518460C2 (en)	2014-06-10
BRPI0413276B8 (en)	2021-05-25
RU2008152033A (en)	2010-07-10
EP2264065B1 (en)	2017-03-08
BE2013C035I2 (en)	2023-12-14
NO2024003I1 (en)	2024-01-16
KR101159559B1 (en)	2012-06-26
LU92213I9 (en)	2018-11-19

Publication	Publication Date	Title
CY2013027I1 (en)	2024-09-20	NEW INSULIN DERIVATIVES
ATE340782T1 (en)	2006-10-15	PIPERIDINEBENZENESULFONAMIDE DERIVATIVES
ATE352550T1 (en)	2007-02-15	CHINAZOLINE DERIVATIVES
CY2015036I2 (en)	2016-06-22	NEW OXAZOLIDINONE DERIVATIVES
ATE420066T1 (en)	2009-01-15	AMIDOACETONITRIL DERIVATIVES
DK2609947T3 (en)	2020-07-06	Plaster-like infusion set
IS8108A (en)	2005-10-31	New compounds
DE602004017700D1 (en)	2008-12-24	TRANSMUKOSEN ADMINISTRATION
DK1606277T3 (en)	2008-08-18	Imidazol-4-yl-ethynyl-pyridine derivatives
IS2656B (en)	2010-08-15	New besimidasol derivatives
DK2107069T3 (en)	2013-04-15	New insulin derivatives
EP1661594A4 (en)	2010-04-14	SYRINGE
DE602004019555D1 (en)	2009-04-02	HETEROCYCLIC 7-AMINOALKYLIDENYLCHINOLONE AND -NAPHTHYRIDONE
IS8228A (en)	2006-01-11	New acetidine compounds
DK1682129T3 (en)	2007-06-11	N-thiazol-2-ylbenzamide derivatives
DK1706373T3 (en)	2010-01-18	Amidoacetonitrile derivatives
IS8292A (en)	2006-02-09	New compounds
IS8045A (en)	2005-09-26	Purin-6-one derivatives
FI20021817A7 (en)	2004-04-15	Cannula
UA6623S (en)	2002-11-15	SYRINGE
FI20030224A0 (en)	2003-02-13	New pharmaceutical uses
SE0301797D0 (en)	2003-06-19	New use V
SE0300106D0 (en)	2003-01-16	New use
SE0302332D0 (en)	2003-08-29	New use I
IS8301A (en)	2006-02-14	New Fusic Acid Derivatives